Berberine chloride hydrate ( Natural Yellow 18 chloride hydrate; 1.25-160 μM; 72 hours) has potential inhibitory effects on the proliferation of four colorectal carcinoma cell lines LoVo, HCT116, SW480, and HT-29.
Berberine chloride hydrate (1.25-160 μM; 24-72 hours) induces a time- and dose-dependent inhibition of LoVo cell growth.
LoVo cells are exposure to Berberine chloride hydrate (10-80 μM) for 24 h. Cell cycle analysis of 40 μM Berberine-treated LoVo cells by flow cytometry shows accumulation of cells in the G2/M phase.
Berberine chloride hydrate (10-80 μM) suppresses cyclin B1, cdc2 and cdc25c protein expression after 24 h, especially at the dose of 80.0 μM.
Cell Proliferation Assay
| Cell Line: | Four colorectal carcinoma cell lines LoVo, HCT116, SW480, and HT-29 |
| Concentration: | 1.25, 2.5, 5, 10, 20, 40, 80, and 160 μM |
| Incubation Time: | 72 hours |
| Result: < /td> | Inhibited the proliferation of four cell lines. The IC 50 ranged from 40.8±4.1 μM (LoVo) to 98.6±2.9 μM (HCT116). |
Cell Proliferation Assay
| Cell Line: | Colorectal carcinoma cell lines LoVo |
| Concentration: | 1.25, 2.5, 5, 10, 20, 40, 80, and 160 μM |
| Incubation Time: | 24, 48, 72 hours |
| Result: | Induced a time- and dose-dependent inhibition of cell growth. By 72 h, 160.0 μM induced 71.1±1.9 % growth inh ibitions in LoVo cells. |
Cell Cycle Analysis
| Cell Line: | LoVo cells |
| Concentration: | 0, 10, 20, 40, or 80 μM |
| Incubation Time: | 24 hours |
| Result: | Exposure to 40.0 μM induced G2/M-phase cell cycle arrest, an increase in the G2/M-phase population and a progressive decline in the G1 population. |
Western Blot Analysis
| Cell Line: | LoVo cells |
| Concentration: | 10, 20, 40, or 80 μM |
| Incubation Time: | 24 hours |
| Result: | Suppressed cyclin B1, cdc2 and cdc25c protein expression. | < /tr>
in vivo
Berberine chloride hydrate (Natural Yellow 18 chloride hydrate; 10, 30, or 50 mg/kg/day; gastrointestinal gavage; for 10 consecutive days) inhibits the growth of human colorectal adenocarcinoma in vivo. Berberine chloride hydrate at Doses of 30 and 50 mg/kg/day taken by gastrointestinal gavage shows inhibitory rates of 33.1% and 45.3% on the human colorectal adenocarcinoma xenograft growth in nude mice.
p>
| Animal Model: < /td> | 5-week-old BALB/c nu/nu mice with human colorectal adenocarcinoma LoVo xenografts |
| Dosage : | 10, 30, or 50 mg/kg/day |
| Administration: | Gastrointestinal gavage; for 10 consecutive days |
| Result: | Showed inhibitory rates of 33.1 % and 45. 3 % at doses of 30 and 50 mg/kg/day. |
target
